Pieter Ferdinand Van Der Meer

Pieter Ferdinand Van Der Meer

Auto-generated profile, based on publicly available information

Pieter Ferdinand Van Der Meer

Department of Product and Process Development Sanquin Blood Bank Amsterdam the Netherlands

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2009 in Transfusion
Verified
Journal Article
Closed access
PDF file
JHJohn R. Hess
John R. Hess
RSRosemary L. Sparrow
Rosemary L. Sparrow
PMPieter F. Van Der Meer
Pieter F. Van Der Meer
JAJason P. Acker
Jason P. Acker
RCRebecca A. Cardigan
Rebecca A. Cardigan
DDDana V. Devine
Dana V. Devine

1 February 2015 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
VSVishal Salunkhe
Vishal Salunkhe
PMPieter F. van der Meer
Pieter F. van der Meer
DKDirk de Korte
Dirk de Korte
JSJerard Seghatchian
Jerard Seghatchian
LGLaura Gutiérrez
Laura Gutiérrez

16 September 2013 in Vox Sanguinis
Verified
Journal Article
Closed access
PDF file
CPC. V. Prowse
C. V. Prowse
DKD. de Korte
D. de Korte
JHJ. R. Hess
J. R. Hess
PMP. F. van der Meer
P. F. van der Meer
TCthe Biomedical Excellence for Safer Transfusion (BEST) Collaborative
the Biomedical Excellence for Safer Transfusion (BEST) Collaborative

12 July 2018 in Blood
Verified
Journal Article
Closed access
PDF file
PMPieter F. van der Meer
Pieter F. van der Meer
PYPaula F. Ypma
Paula F. Ypma
NGNan van Geloven
Nan van Geloven
JHJoost A. van Hilten
Joost A. van Hilten
RWRinie J. van Wordragen-Vlaswinkel
Rinie J. van Wordragen-Vlaswinkel
JKJean-Louis H. Kerkhoffs
Jean-Louis H. Kerkhoffs
Pathogen inactivation of platelet concentrates reduces the risk for blood-borne infections. However, its effect on platelet function and hemostatic efficacy of transfusion is unclear. We conducted a randomized noninferiority trial comparing the efficacy of pathogen-inactivated platelets using riboflavin and UV B illumination technology (intervention) compared with standard plasma-stored platelets (control) for the prevention of bleeding in patients with hematologic malignancies and thrombocytopenia. The primary outcome parameter was the proportion of transfusion-treatment periods in which the patient had grade 2 or higher bleeding, as defined by World Health Organization criteria. Between November 2010 and April 2016, 469 unique patients were randomized to 567 transfusion-treatment periods (283 in the control arm, 284 in the intervention arm). There was a 3% absolute difference in grade 2 or higher bleeding in the intention-to-treat analysis: 51% of the transfusion-treatment periods in the control arm and 54% in the intervention arm (95% confidence interval [CI], −6 to 11; P = .012 for noninferiority). However, in the per-protocol analysis, the difference in grade 2 or higher bleeding was 8%: 44% in the control arm and 52% in the intervention arm (95% CI −2 to 18; P = .19 for noninferiority). Transfusion increment parameters were ∼50% lower in the intervention arm. There was no difference in the proportion of patients developing HLA class I alloantibodies. In conclusion, the noninferiority criterion for pathogen-inactivated platelets was met in the intention-to-treat analysis. This finding was not demonstrated in the per-protocol analysis. This trial was registered at The Netherlands National Trial Registry as #NTR2106 and at www.clinicaltrials.gov as #NCT02783313. Publisher9s Note: There is a Blood Commentary on this article in this issue. Key Points Pathogen-inactivated platelets were noninferior in preventing bleeding only in intention-to-treat analysis. In contrast to animal models, alloimmunization could not be prevented when using pathogen-inactivated platelets. Visual Abstract

1 May 2010 in Vox Sanguinis
Verified
Journal Article
Closed access
PDF file
PMP. F. van der Meer
P. F. van der Meer
JKJ.-L. Kerkhoffs
J.-L. Kerkhoffs
JCJ. Curvers
J. Curvers
JSJ. Scharenberg
J. Scharenberg
DKD. de Korte
D. de Korte
JWJ. de Wildt-Eggen
J. de Wildt-Eggen

9 March 2018 in Transfusion Medicine and Hemotherapy
Verified
Journal Article
Open access
PDF file
PMPieter F. van der Meer
Pieter F. van der Meer
DKDirk de Korte
Dirk de Korte
Platelet additive solutions (PASs) have undergone many reformulations in order to further improve platelet storage. Studies of platelets stored in PAS-F (containing acetate, magnesium and potassium as key constituents) showed that platelets may be stored for 13 days with recovery and survival outcomes that are equal or even superior to 7-day stored platelets in plasma. Clinically, patients transfused with platelets in PAS have fewer allergic reactions, while for febrile reactions data are conflicting. Transfusion-related acute lung injury (TRALI) occurs less frequently if PAS is used for buffy coat-derived platelets, but for apheresis platelets there is no difference. For PAS-B and PAS-C, corrected count increments (CCIs) are lower than for platelets stored in plasma, but for PAS-E (like PAS-F also with acetate, magnesium and potassium but with additional phosphate), though limited data is available in the literature, the CCIs seem to be comparable to those observed for platelets in plasma. With platelets in PAS, there is an accumulated dilution effect of anticoagulant and PAS as well as a loss of number and function (due to storage and/or pathogen inactivation treatment) of platelets, of which it is not clear how this impacts clinical outcomes of patients undergoing massive transfusion. Worst-case in vitro studies, where the entire plasma fraction is replaced by supernatant of platelets in PAS, do show an effect on the ability of reconstituted whole blood to clot, but in a more realistic scenario, functional clotting parameters are not different. In this review, recent laboratory and clinical data are discussed, focusing on studies published after 2010.